Background: Adult height has been related to organ-specific malignancies in relatively few studies. Findings are discrepant for some sites and several studies are subject to a series of methodological limitations.
introduction
Over the last decade there has been a re-emergence of interest in the early life origins of chronic disease in adulthood [1] . There is, however, a paucity of studies with extended follow-up of children with which to examine these associations. Accordingly, investigators have related indices of early life factors assessed in cohorts of middle-aged persons to subsequent health experience. These indices include social factors, such as adult recall of childhood socioeconomic position [2] , and physical characteristics, chiefly height [3] . Height may be regarded as a marker of early life illness, nutrition or psychosocial stress [3] , and has the advantage of remaining relatively stable from early to late adulthood.
In industrialised populations, an inverse association between height and all-cause mortality is apparent. Thus, taller persons experience lower death rates in cohorts drawn from Britain [4, 5] , Scandinavia [6] [7] [8] [9] , Finland [9] , the USA [10] and South Korea [11] . That these associations are generally weak may be ascribed to the apparent opposing gradients for height in relation to two major chronic diseases among older persons: cardiovascular disease and all cancers combined. Thus, while the former association is inverse [5, 12] , the latter has been shown to be positive [13] . Within subtypes of malignancy, a heterogeneous relation with height is also apparent [14] . Although greater stature is associated with elevated rates of carcinoma of the colorectum, lung, prostate and breast (in women), there is a suggestion of an inverse relation with neoplasm of the stomach and oesophagus in some studies [14] . For other cancer subtypes, findings are either discrepant (e.g. renal, pancreas) or there are too few studies from which to draw clear conclusions about links with height (e.g. bladder, haematopoetic, skin) [14] .
In addition to this weak evidence base for height in relation to some malignancies, several existing studies are subject to a series of methodological shortcomings. First, the majority utilise a case-control design in which the problem of selection and information bias is more acute than in prospective cohort studies. Secondly, in the prospective studies that do exist, low statistical power is commonplace owing to a limited number of cases. Also, investigators often focus on one type of malignancy, which limits conclusions about specificity of association [14] and therefore insights into causality. Thirdly, many datasets lack information on potentially important confounding variables such as socioeconomic circumstances [15] , adiposity and, critically for many malignancies, tobacco use [14] . Importantly, when available adjusting for such covariates seems to attenuate the height-cancer effect [14] .
In the Whitehall study, over 18 000 male, middle-aged, London-based government employees participated in a medical examination in the late 1960s that included measurement of their height and a range of collateral data [16] . In extended (maximum 35 year) mortality surveillance of this cohort there have been over 3000 cancer deaths. We are therefore able to address these issues of prospective study scarcity and methodological shortcomings. In earlier (maximum 27 year) follow-ups of this cohort, reduced risks of total mortality [4] and cardiovascular disease [17] , and elevated rates of some cancers [17, 18] , were apparent in taller men. The present analysis allows us to examine the link between height and a much greater range of organ-specific malignancies than previously examined in this study.
materials and methods
In the Whitehall study, data were collected on 18 403 non-industrial, London-based, male government employees aged from 40 to 64 years when examined between September 1967 and January 1970, representing a 74% response. This involved the completion of a study questionnaire and participation in a medical examination, both of which have been described in detail elsewhere [16] . In brief, the questionnaire included enquiries regarding civil service employment grade (an indicator of socioeconomic position [19] ), smoking habits, intermittent claudication, angina, chronic bronchitis, marital status, physical activity, unexplained weight loss in the preceding year and prescribed drug use. Forced vital capacity, ischaemia, fasting plasma cholesterol, post-challenge 2-h blood glucose, blood pressure, and triceps skinfold thickness were all determined using standardised protocols. Height was measured with the subject wearing shoes and standing with their back to a measuring rod. Readings were taken to the nearest half inch below the point of measurement [20] . For the purposes of the present analyses, all readings were converted to centimetres.
ascertainment of cancer mortality
The records of 18 245 men (99.1% of cohort members) were traced and flagged using the procedures of the National Health Service Central Registry until 31 December 2002. Among the 11 710 men who died, 91.6% of death certificates were coded according to the 8th revision of the International Classification of Diseases (ICD) [21] , 7% according to the 9th revision [22] and 1.4% according to the 10th revision [23] . The category of all malignant neoplasms (ICD-8: 140-208; ICD-9: 140-209; ICD-10: C00-C97)-referred to as 'all-cancers'-was divided into individual organs. In ascending order of ICD-8/9 code, these were: oesophagus (ICD-8/9: 150; ICD-10: C15); stomach (ICD-8/9: 151; ICD-10: C16); colon (ICD-8/9: 153; ICD-10: C18); rectum (ICD-8/9: 154; ICD-10: C19); liver (ICD-8/9: 155-156; ICD-10: C22-C24); pancreas (ICD-8/9: 157; ICD-10: C25); trachea, bronchus and lung (ICD-8/9: 162; ICD-10: C33-C34; referred to as 'lung cancer'); skin We also grouped cancers into those for which tobacco smoking appears to have an aetiological role, and those for which it does not. This was based on the hypothesis that any influence of greater stature on smoking-related cancers would be obliterated by the substantially greater carcinogenic effects of tobacco smoke. We therefore anticipated a null or inverse relation between height and malignancies related to smoking (increased levels of smoking are apparent in shorter individuals), and a positive relation between height and malignancies not related to smoking. The following cancers were designated as being related to tobacco smoking: lip, oral cavity and pharynx (not including salivary gland; ICD-8/9: 140, 141, 143-149; ICD 10: C00-C06, C09-C15); oesophagus (see above); pancreas (see above); respiratory and intrathoracic organs (ICD-8: 160-163; ICD-9: 160-165; ICD-10: C30-C39); and urinary tract (ICD-8/9: 188-189; ICD-10: C64-C68). All other cancers were denoted as not being related to smoking. While updating these analyses an error was discovered in the coding of smoking-related cancers utilised in a report based on an earlier (27 year) follow-up of the Whitehall study [18] . In this previous publication [18] , the following cancers were incorrectly assigned as being related to smoking: stomach (ICD-8/9: 151); small intestine, including duodenum (152); colon (153); rectum (154); liver (155); gallbladder (156); retroperitoneum and peritoneum (158); other and ill-defined sites within the digestive organs and peritoneum (159). This error has been corrected in the present analyses and we comment on the implications of this for the results in the Discussion.
data analyses
A total of 17 353 men (94.3% of the original cohort) had data for height and all potential covariates, and these form the sample for the analyses. The cause of death for 41 of these men was unknown and they were excluded from all analyses of cancer mortality outcomes. In all analyses we quantified the relation of cancer with height, categorised into four groups of similar sample size (<171, 171-175.9, 176-180.9 and ‡181 cm) and as a continuous measure expressed in 5 cm (increasing) increments.
In analyses of baseline characteristics according to height categories, the prevalence of the former were adjusted for age (in 5-year groups) by the direct standardisation method. Trends in these proportions were examined using the Mantel-Haenszel test. For continuous variables, least squares means were used to present the age-adjusted means, with tests for trend across height groups computed by fitting a linear trend term. Mortality rates in each height category were calculated using person-years at risk. These rates were standardised for age at entry by the direct method using the study population as standard.
Hazard ratios and accompanying 95% confidence intervals (CIs) were computed for the relation of height with each mortality outcome using Cox's proportional hazards regression model [24] with follow-up period as the time scale. In these analyses, indicator variables were used for analyses according to the four height categories. P values for trend across these categories were computed by fitting a single linear term for the height categories. Analyses of height as a continuous measure used a single linear term. Statistical models were initially adjusted for age and then for other potential covariates. For the purposes of statistical adjustment, age, triceps skinfold thickness, plasma cholesterol, forced vital capacity (used in lung cancer analyses only), body mass index (BMI) and systolic blood pressure were fitted as continuous variables. The remaining factors were fitted as categorical variables.
During the baseline study, the physical activity enquiries on the questionnaire were modified. Levels of this behaviour were determined from either an item about travel activity [25] (administered to approximately two-thirds of men) or leisure activities [26] (administered to the remainder). Analyses of the height-total cancer relationship indicated that there was no confounding effect due to questionnaire type. Smoking status was grouped into four categories (never, ex-smoker, current pipe or cigar smoker, and current cigarette smoker) together with additional adjustment for the number of cigarettes smoked per day in current smokers. Existing disease at study entry was defined as a positive response to enquiries regarding a range of health conditions: use of blood pressure-lowering medication, unexplained weight loss in the preceding year, ischaemia [27] , diabetes [28] , intermittent claudication, physician-diagnosed heart problems or high blood pressure (one question), dyspnoea, and bronchitis.
In cohort studies of height and disease risk, morbidity, including cancer, whether detected or undetected at study induction, may cause a reduction in height. Referred to as shrinkage, examples include obstructive lung disease which may lead to kyphosis, a pronounced outward curvature of the spine. This would have the effect of decreasing the magnitude of an underlying positive relation (generally apparent in studies where cancer is the outcome of interest) and increasing the magnitude of an inverse relation (generally apparent in studies where total mortality and, particularly, cardiovascular disease are the outcomes of interest). To address this issue of reverse causality we adopted two approaches. First, to explore the role of clinically manifest illness we adjusted for disease at study entry (see above definition). Secondly, to explore the role of occult disease, we excluded deaths in the first 10 years of mortality surveillance and repeated our analyses. In so doing, we reasoned that a large proportion of deaths attributable to cancer, if present at study induction, would have occurred within this time frame. All statistical analyses were conducted using SAS computer software [29] .
results
In Table 1 the associations between height and a range of baseline characteristics are presented. In general, the more favourable levels of each characteristic were apparent in the taller men. The only exception was triceps skinfold thickness, which was positively related to height (P trend <0.001). In comparison to their shorter colleagues, taller men were younger, had greater lung function, lower BMI and cholesterol levels, and a reduced prevalence of existing disease at baseline, impaired glucose tolerance and diabetes (all P trend <0.001). Taller men were also less likely to be physically inactive, smoke cigarettes, or be without a partner (all P trend <0.001). There was a marked gradient in employment grade across the height groups, with the proportion of workers of low socioeconomic position in the tallest group, half that of men in the shortest group (P trend <0.001).
In Tables 2-5 hazards ratios with accompanying 95% CIs for height in relation to selected mortality outcomes are presented. There were 11 099 deaths during follow-up, 3101 (28%) of which were ascribed to cancer. Types of cancer are presented in decreasing order of incidence. Total mortality, included as an outcome for the purposes of completeness, was inversely related to stature [hazard ratio per 5 cm increase in height (95% CI): 0.96 (0.94, 0.97)], however, this gradient was effectively eliminated following full adjustment [0.99 (0.98, 1.01)]. In ageadjusted analyses (Table 2) , height was positively associated with cancer of combined sites [1.03 (1.00, 1.05)], but not lung cancer mortality [1.00 (0.95, 1.06)]. However, a stronger positive association for carcinoma of the lung was seen following adjustment for socioeconomic position and other potential confounding and mediating variables, but was weakened somewhat after individuals who died in the first 10 years of follow-up were excluded from the analysis. There was also a suggestion that taller men experienced an elevated risk of prostate cancer, although statistical significance at conventional levels was lacking in several of the analyses.
In Table 3 , stature showed no relation with either deaths due to lymphoma or pancreatic cancer. The suggestion of a reduced rate of stomach cancer deaths in taller men apparent in ageadjusted analyses [0.92 (0.83, 1.02)] was essentially lost when adjustment was made for all covariates. Point estimates for carcinoma of the bladder were raised in taller men, but in a nonstepwise manner (P trend = 0.48 in an age-adjusted analysis). These effects became stronger after deaths in the first 10 years of surveillance were dropped from the analysis. A similar observation was made when oesophageal cancer and leukaemia 
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were the outcomes of interest (Table 4) . A positive, nonincremental height-kidney cancer relation was apparent, although statistical power in this analysis was low owing to a small number of cases. There was little evidence of an association between stature and malignancy of the liver. Although based on a small number of deaths as evidenced by the very wide CIs, mortality rates from skin cancer ( . When we combined site-specific cancers into those for which smoking has, and has not, been implicated in their aetiology, we found a similar positive relation with height for each after adjustment for all covariates. We computed a test for heterogeneity in the height-cancer gradient across the fourteen site-specific end points, and found no indication of heterogeneity in either the age-(P = 0.18) or original article Annals of Oncology multiply-adjusted analyses (P = 0.43). With the suggestion of change in the strength of the height-malignancy association for some cancer sites after the exclusion of deaths in the first 10 years of mortality surveillance, we examined whether there was any effect modification according to follow-up duration. For 13 of the 14 individual cancer sites there was no such evidence (P value for non-proportionality of hazards ratios in multiply-adjusted analyses ranged between 0.24 and 0.91). The only exception was oesophageal cancer (P <0.001).
We also explored effect modification across strata of other key collateral data. These were smoking (stratified as: never, former, current), overweight/obesity (BMI <25 kg/m 2 or ‡25 kg/m 2 ) and prevalent disease at study induction (absence versus presence). We chose to examine only all-cancers as an outcome, because there was little evidence of statistical heterogeneity of the height-outcome gradient across the cancer subtypes (see above), suggesting our findings would hold for site-specific end points. Using tests for heterogeneity in the height-cancer association across strata of these variables, no evidence of effect 
discussion
In the present study of a large, well characterised cohort of London-based, male government employees in which >3000 cancer deaths had occurred during follow-up, the relation of height to the 17 cancer mortality outcomes (14 sites) was essentially either positive or null. Thus, there was evidence that taller men experienced elevated mortality rates from cancer of combined sites, cancers related and unrelated to tobacco smoke, and cancer of the lung, the prostate, the bladder, the kidney, the skin and leukaemia. That the positive height-cancer gradients we found were generally of low magnitude is congruent with the conclusions of a recent review [14] . In a separate analysis using data from the most recent follow-up of the Whitehall study, we have shown height to be inversely related cardiovascular disease and stroke, a finding that also generally accords with other studies [30] [31] [32] . cholesterol, forced vital capacity (only for lung cancer analysis), impaired glucose tolerance, diabetes and disease at entry. e Analyses based on a subgroup in which persons who died in the first 10 years of mortality surveillance were excluded (number of deaths in parentheses).
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A comprehensive review suggests that prostate and lung cancer are among the few malignancies to be consistently linked to stature in men (the association is positive) [14] . Subsequent reports do not, however, find an association [11, 33] . In the analyses reported herein, the direct height-lung cancer relation was further strengthened after controlling for covariates that included smoking, an adjustment that has not been made in all studies [17, 34, 35] . Similar observations were made when prostate cancer mortality was the outcome of interest. In contrast to these and several other neoplasms, oesophageal cancer is one of the few organ-specific carcinomas to demonstrate inverse relations with stature [17, 36, 37] , although this finding is not universal [11, 38, 39] . While an inverse association was also found in an earlier (maximum 20 year) follow-up of the present cohort [17] , in this current analysis based on a longer period of surveillance with a larger number of deaths, no overall heightoesophageal carcinoma association is apparent. As implicated by the findings of this earlier report and confirmed in further analyses here, the relation between this malignancy and height was dependent upon the duration of follow-up. Although several investigators have related height to colorectal cancer [5, [39] [40] [41] , given the apparent dissimilar aetiology of the neoplasms that comprise this end point [42] , calls have been made to report separate exposure-disease effects for colon and rectal cancer. However, in the present study, in keeping with some others [38, 43, 44] , we found no evidence to support a differential effect for height. Lymphoma and leukaemia are also often collapsed into a single outcome (haematopoetic cancers) in studies of stature and cancer. In the present analysis, a clear height-lymphoma gradient was not apparent, while there was evidence of a positive, incremental relation when leukaemia death was the outcome of interest. Other than an earlier follow-up of the present cohort [17] , to our knowledge, only data from a Scottish study has been utilised to examine the height-leukaemia link [5] and there was no evidence of association. While the graded stature-cancer effect found for leukaemia was not apparent when we correlated height with either carcinoma of the bladder or kidney, several of the point estimates were nonetheless significantly raised. Of the three cohort studies [34, 38, 39] identified by Gunnell et al. [14] to have examined the influence of height on bladder cancer, none found an association. We are not aware of any publications subsequent to this review.
The literature reporting on the height-renal cancer relation is also modest in size and reveals mixed results, with two [38, 45] e Analyses based on a subgroup in which persons who died in the first 10 years of mortality surveillance were excluded (number of deaths in parentheses).
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out of three cohort studies [38, 39, 45] finding a positive association, as we have. In one study where a sample of Norwegian men and women [45] was two orders of magnitude larger than any other previous investigation of risk, a positive, monotonic height-renal cancer gradient was found in men. Although collateral data were scarce in this study-there were, for instance, no data on socioeconomic position [15] -a subgroup analysis on those in which information on smoking history had been collected showed similar effects following statistical adjustment for this behaviour. When we dichotomised cancers into those related to smoking and those not, similar positive associations with height were apparent for both outcomes after adjustment for covariates. An earlier follow-up of the Whitehall cohort found a differential association with height for these cancer groups [18] , whereby a positive gradient with height was seen for cancers unrelated to smoking but not those related to smoking. Reasoning that the discrepant results offered by these respective reports might be a reflection of this coding error (see Materials and methods for description), we re-analysed data for the earlier follow-up. In analyses adjusted for age, employment grade and smoking, the association of height with both groups of cancers was, in fact, positive and of similar magnitude (P trend = 0.09 in both groups) to those found in the present paper.
plausible mechanisms
Rather than tall stature in itself 'causing' cancer, it is much more likely that stature is an environmental and/or genetic marker of risk [3] . In the present study we were unable to investigate genetic factors. With regard to environmental factors, by adjusting for socioeconomic position, BMI and smoking, it was apparent that these indices, at least when assessed in middle-age, are unlikely to have generated any height-cancer effects. Other possible explanations for a height-cancer relation include the link between stature and an array of early life exposures such as health status, social conditions and energy intake. Given the suggestion that childhood illness and poverty correlate with an increased risk of some adult cancers [46] , but are themselves inversely related to adult height, they are largely ruled out as explanations for the positive height-malignancy gradients apparent in the present study. One exception may be stomach cancer, which was negatively related to height in age-adjusted analyses herein, as it was in multiply-adjusted models in another cohort [5] . In this Scottish study [5] , the authors advanced Helicobacter pylori infection as the underlying cause of this gradient. Associated with suboptimal growth [47] , this biological organism has also been identified as a predictor of stomach cancer in some [48] , but not all [49] , reports.
In the positive height-cancer gradients that predominate in the present analyses, stature may be a proxy of childhood food intake. It has long been recognised that animals who are fed a calorie-constrained, but otherwise micronutrient-balanced diet, subsequently experience lower cancer incidence than their overfed counterparts [50, 51] . In perhaps the only study of humans to date, this finding was replicated in individuals who participated in a inter-war dietary survey as children who were then followed over several decades into later life [52] . It has been proposed that underlying this relation may be reduced levels of insulin-like growth factors (IGF), which correlate directly with caloric intake (in animals) [53] , height in children [54] and risk of colorectal and prostate cancer in adult humans [55] . IGF levels [56] and height [5, 12] are also inversely related to coronary heart disease in some studies. In support of an IGFmalignancy link, we found a positive stature-prostate cancer gradient; however, no association was observed for colorectal cancer.
A separate explanation for the positive height-cancer effects evident in the present analysis simply posits that taller people have larger bodies and therefore more cells that may potentially undergo malignant transformation to frank cancer. A priori, this was our hypothesis when we explored the link between stature and skin cancer. While our finding of a strong positive relation is supported by two [57, 58] of the three [38, 57, 58] prospective cohort studies that have also examined this association, it should nonetheless be viewed with caution owing to the very low number of deaths on which it is based (there were only two skin cancer deaths in the shortest group of men).
alternative explanations
Plausible non-causal explanations for some of the associations reported herein are chance, bias and confounding. A large number of statistical tests were necessarily conducted given the high number of health end points, so raising the problem of multiple comparisons where some positive results surface by chance alone. While selection bias is a potential concern in cohort studies, this is unlikely to be so in the Whitehall study, where loss to follow-up was very low (<1%). The principal impediment to interpretation of an association in observational epidemiology is confounding [59] . In contrast to some other studies [36, 45, 60] , we controlled for a number of important adult risk factors for cancer: smoking, adiposity and socioeconomic disadvantage, thereby minimising confounding as a concern. It was notable that for some cancers (e.g. lung and all those related to smoking), a relation with height only emerged after adjustment for covariates, particularly employment grade. Given the positive association between height and employment grade, and the negative association between grade and some malignancies, such negative confounding is to be expected [18, 52] .
conclusions
In this large, well-characterised cohort of government employees, there was evidence that taller men experienced elevated mortality rates from cancer of combined sites, the lung, the prostate, the bladder, the kidney, the skin and leukaemia. Exposures in early life which correlate with adult height, such as caloric intake, may, at least partially, explain these associations. 
